Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics Deal validates Jeito’s unique investment model of selecting high–quality assets developed by world-leading teams in therapeutic areas with high unmet need Paris, France, November 29th 2022 – Jeito Capital (“Jeito”), the largest fully independent international private equity firm dedicated to […]

Read More

Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics Deal validates Jeito’s unique investment model of selecting high–quality assets developed by world-leading teams in therapeutic areas with high unmet need Paris, France, November 29th 2022 – Jeito Capital (“Jeito”), the largest fully independent international private equity firm dedicated to […]

Read More